?

Contract Manufacturing Organizations (CMO) in Eastern Europe - Inconsistent Demand and Competition from Asia Raises Concerns

Date: October 1, 2010
Pages: 95
Price:
US$ 3,500.00 US$ 2,800.00
Offer valid until June 7, 2015!
License [?]:
Publisher: GBI Research
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CD0AEACB4CFEN
Leaflet:

Download PDF Leaflet

Sample:

Download Free Sample

Contract Manufacturing Organizations (CMO) in Eastern Europe - Inconsistent Demand and Competition from Asia Raises Concerns

Summary

GBI Research, the leading business intelligence provider, has released its latest report, “Contract Manufacturing Organizations (CMO) in Eastern Europe
  • Inconsistent Demand and Competition from Asia Raises Concerns” that provides key data, information and analysis of the major trends and issues affecting the Contract Manufacturing Organizations (CMO) in Eastern Europe. The report provides a comprehensive insight into Contract Manufacturing Organizations (CMO) in Eastern Europe. The report also provides a detailed analysis of Contract Manufacturing Organizations (CMO) in Eastern Europe market characterization in terms of its market size, segmentation by key CMO and the major market drivers and barriers. The report also provides competitive landscape of the market that profiles key market players along with their brief business description, pipeline, major products and major M&A and partnership deals.

    Scope

    The scope of the report includes:
    • Detailed overview of CMO’s along with their efficiency and limitation
    • Key market drivers and restraints shaping the CMO’s
    • Competitive landscape analysis with competitive profiling of leading companies such as Analysis of partnership deals
    • Analysis of M&A deals


    Reasons to buy

    The report will enhance your decision making capability. It will allow you to
    • Develop better strategies for CMO’s by understanding the market dynamics.
    • Develop market-entry and market expansion strategies by identifying the key cancer areas for high growth and high opportunities
    • Understand the factors shaping the CMO’s
    • Identify the key players
    • Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.
  • 1 TABLE OF CONTENTS

    1.1 List of Tables
    1.2 List of Figures

    2 INTRODUCTION

    2.1 GBI Research Guide

    3 OVERVIEW OF THE CMO INDUSTRY

    3.1 Current Status of Pharmaceutical Industry
    3.2 The Need to Outsource for Pharmaceutical Companies
      3.2.1 Reduction in Physical Assets
      3.2.2 Restructuring of Product Portfolio
      3.2.3 Downsizing Manufacturing
      3.2.4 Reduction in R&D Spending
    3.3 What CMOs are and Reasons for Outsourcing to Them
      3.3.1 Different Types of CMOs and the Range of Services Provided by Them
      3.3.2 How Does Outsourcing to CMOs Take Place?
      3.3.3 Key Outsourcing Models
      3.3.4 Key Benefits of Outsourcing

    4 CONTRACT MANUFACTURING IN EASTERN EUROPE - MARKET CHARACTERIZATION

    4.1 Market Forecasts

    5 GEOGRAPHICAL LANDSCAPE

    5.1 Comparative Analysis of Eastern European Countries
    5.2 Infrastructural Facilities – Railways, Roadways, Airways, Power and Overall Logistics Support
    5.3 Labor - Availability of Skilled Labor at Affordable Rates and Labor Flexibility
    5.4 Broad Economic Indicators – GDP, Availability of Credit, Taxation Policies
    5.5 Ease of Doing Business – Overall Government and Regulatory Support
      5.5.1 Key Takeaway
    5.6 Individual Strengths and Weaknesses for Each Country
      5.6.1 Poland
      5.6.2 Czech Republic
      5.6.3 Lithuania
      5.6.4 Ukraine
      5.6.5 Hungary
      5.6.6 Slovakia
      5.6.7 Slovenia
    5.7 Analysis of Other Emerging CMO markets
      5.7.1 Chinese CMO Market
      5.7.2 Indian CMO Market

    6 MARKET DRIVERS AND RESTRAINTS

    6.1 Drivers
      6.1.1 Availability of Low-cost Skilled Manpower
      6.1.2 Better Infrastructure and Government Policies
      6.1.3 Increased Consumptions of Generics
      6.1.4 Better Intellectual Property Rights Protection
      6.1.5 Increasing Uptake of Biologics and Entry of Biosimilars into Market
    6.2 Restraints
      6.2.1 Competition from Low-cost Asian CMOs
      6.2.2 Capacity Utilization Issues Affecting the Profitability of CMOs
      6.2.3 Reduced Number of New Drug Approvals
      6.2.4 Complex Cost Structures in Outsourcing

    7 REGULATORY LANDSCAPE

    7.1 EU GMP
      7.1.1 EU cGMP Guidelines for API Manufacturing
      7.1.2 Key Changes in EU GMP Guidelines
    7.2 PIC/S

    8 PROMINENT PLAYERS

    8.1 Polpharma S.A.
      8.1.1 Services Offered
    8.2 Hasco-Lek S.A.
      8.2.1 Services Offered
    8.3 Sanitas AB (Sanitas Group)
      8.3.1 Pharmaceutical Company JELFA SA
      8.3.2 Laboratorium Farmaceutyczne Homeofarm sp. z o.o.
    8.4 Lonza Biotec sro
      8.4.1 Services Offered
    8.5 Grindeks A.S.
      8.5.1 Services Offered
    8.6 Galilaeus Oy
      8.6.1 Services Offered
    8.7 FSP Galena
      8.7.1 Services Offered
    8.8 Noventis sro
      8.8.1 Services offered
    8.9 Zentiva N.V.
      8.9.1 Services Offered
    8.10 SVUS Pharma a.s.
      8.10.1 Services offered
    8.11 Notable CMOs in Eastern Europe
      8.11.1 Nycomed
      8.11.2 Polfa Tarchomin S.A.
      8.11.3 Biogened S.A.
      8.11.4 Pliva Lachema a.s.
      8.11.5 Aflofarm
      8.11.6 TAPI

    9 MAJOR EVENTS AND TRENDS IN THE CMO INDUSTRY

    9.1 US Healthcare Reforms in 2010 Will Affect CMOs Positively due to Increased Demand for Medicines in the US.
    9.2 Upcoming Blockbuster Drugs will Create a Positive Impact on the CMO Industry
    9.3 Increased Focus on Emerging Markets by Major Pharmaceutical Companies will Affect CMOs Positively
    9.4 Developments Leading to an Anti-counterfeiting Trade Agreement will Affect CMOs Positively
    9.5 Increased M&A Activity During 2009-10 is Likely to Affect the CMO Business Positively
    9.6 Tightening of GMP Guidelines by the FDA and the EU in Near Future will Increase Costs for the CMOs and will Negatively Affect their Profitability.
    9.7 Lower Capacity Utilization in the Biologics Manufacturing Industry is Negatively Affecting the Profitability of the CMOs
    9.8 Drug Price Cuts Across Western Europe will Negatively Affect the CMOs

    10 APPENDIX

    10.1 Market Definitions
    10.2 Abbreviations
    10.3 Research Methodology
      10.3.1 Coverage
      10.3.2 Secondary Research
      10.3.3 Primary Research
      10.3.4 Expert Panel Validation
    10.4 Contact Us
    10.5 Disclaimer
    10.6 Sources

    LIST OF TABLES

    Table 1: Contract Manufacturing in Eastern Europe, Market Characterization, Eastern Europe CMO Market Size, $bn, 2007-2016
    Table 2: Market Drivers, All Employees: Indexes of Hourly Compensation Costs (United States = 100)
    Table 3: Market Drivers, Better Government Policies Supporting Business Operations in Eastern Europe
    Table 4: Market Drivers, Major Drug Patent Expirations, 2010-2016
    Table 5: PIC/S Members from Eastern Europe
    Table 6: Promising Biologic Drugs likely to get Approved by FDA in 2010

    LIST OF FIGURES

    Figure 1: Cost Optimization Steps in the Pharmaceutical Industry
    Figure 2: Impact Analysis of Various Cost Optimization Methods
    Figure 3: Global CMO Industry Structure
    Figure 4: Process for Selection of CMO and Management of Outsourcing Project
    Figure 5: Key Benefits of Outsourcing to CMOs
    Figure 6: Increasing Share of CMOs in Overall Pharmaceutical Manufacturing
    Figure 7: Revenue Split of Global CMO Market by Geography
    Figure 8: Break-up of Global CMO Market by Services Provided
    Figure 9: Contract Manufacturing in Eastern Europe, Market Characterization, Eastern Europe CMO Market Size ($bn), 2007-2016
    Figure 10: Parameters Considered for Ranking of Different Eastern European Nations
    Figure 11: Ranking on Infrastructure of Different Eastern European Nations
    Figure 12: Rankings for Attractiveness of Labor of Different Eastern European Nations
    Figure 13: Rankings for Broad Economic Indicators of Different Eastern European Nations
    Figure 14: Rankings for Ease of Doing Business for Different Eastern European Nations
    Figure 15: Ranks for Overall Business Attractiveness
    Figure 16: Geographical Landscape, Strengths and Weaknesses, Poland
    Figure 17: Geographical Landscape, Strengths and Weaknesses, Czech Republic
    Figure 18: Geographical Landscape, Strengths and Weaknesses, Lithuania
    Figure 19: Geographical Landscape, Strengths and Weaknesses, Ukraine
    Figure 20: Geographical Landscape, Strengths and Weaknesses, Hungary
    Figure 21: Geographical Landscape, Strengths and Weaknesses, Slovakia
    Figure 22: Geographical Landscape, Strengths and Weaknesses, Slovenia
    Figure 23: Contract Manufacturing in Eastern Europe, Market Driver and Restraints
    Figure 24: Market Drivers, Difference in Hourly Wage Costs in Euro Area v/s Eastern Europe
    Figure 25: Market Drivers, Percentage of Tertiary Graduates by Disciplines, Eastern Europe v/s Developed Nations
    Figure 26: Market Drivers, Increasing Generics Opportunities Due to Patent Expiries for Major Drugs
    Figure 27: Market Drivers, Market Opportunity for CMOs Due to Patent Expiry for Blockbuster Drugs
    Figure 28: Market Drivers, Increased Opportunities for CMOs Due to Generics Manufacturing
    Figure 29: Market Drivers, IPR Protection Eastern European v/s Asian CMO Markets
    Figure 30: Market Drivers, Growth in Global Biologics Market, 2009-2016
    Figure 31: Market Drivers, Analysis of Increasing Opportunities for Biologics Manufacturing for CMOs
    Figure 32: Market Drivers, Increased Biologics Manufacturing Opportunities for CMOs
    Figure 33: Market Restraints, Cost Comparison Between Eastern European and Asian CMOs
    Figure 34: Market Restraints, Reduction in Drug Approval Rates by FDA Affecting CMOs
    Figure 35: Market Restraints, Opportunities Lost by CMOs Due to Reduced Approval Rates by FDA
    Figure 36: Regulatory Landscape, Manufacturing Regulatory Framework in Eastern Europe
    Figure 37: Steps in API Manufacturing Governed by EU GMP Guidelines
    Figure 38: Prominent Players, Polpharma S.A.
    Figure 39: Prominent Players, Hasco-Lek S.A.
    Figure 40: Prominent Players, Sanitas Group
    Figure 41: Prominent Players, Lonza Biotec sro
    Figure 42: Prominent Players, Grindeks A.S.
    Figure 43: Prominent Players, Galilaeus Oy
    Figure 44: Prominent Players. FSP Galena
    Figure 45: Prominent Players, Noventis sro
    Figure 46: Prominent Players, Zentiva N.V.
    Figure 47: Prominent Players, SVUS Pharma a.s
    Figure 48: Comparison of CMOs
    Figure 49: Major Trends and Events and Their Impact on the CMO Industry

    COMPANIES MENTIONED

    Skip to top


    Ask Your Question

    Contract Manufacturing Organizations (CMO) in Eastern Europe - Inconsistent Demand and Competition from Asia Raises Concerns
    Company name*:
    Contact person*:
    Phone/fax*:
    Email*:
    Request invoice
    Your enquiry:
    Please click on a Check Box below to confirm you are not a robot: